CVS Health posted a strong first-quarter performance for 2026, beating analyst expectations for both revenue and earnings per share [1].

This growth suggests a recovery for the healthcare giant as it integrates new acquisitions and stabilizes its benefits segment. The results have sparked a stock rally, leading some analysts to say the company's valuation remains low relative to its performance [1], [2].

Financial reports show the company generated $100.4 billion [1] in first-quarter revenue. This represents a 6.2% [1] increase year-over-year. The figure significantly outperformed the analyst estimate of $94.4 billion [1].

Earnings per share (EPS) also saw a substantial climb. CVS Health reported an EPS of $2.30 [1], which is 62% [1] higher than the previous year. This result beat the analyst estimate of $1.93 [1].

Several factors contributed to the rebound. The company saw a recovery in its health-care benefits segment and a surge in sales following the acquisition of Rite Aid stores [3], [4]. These movements helped drive the overall increase in revenue and profitability during the start of the year.

Market analysts said that the stock rally may be in its early stages [2], [3]. They pointed to the gap between the company's current valuation and its actual earnings growth as a sign of potential for further increases [1], [2].

“CVS Health reported an EPS of $2.30, which is 62% higher than the previous year.”

The financial results indicate that CVS Health is successfully leveraging its vertical integration strategy. By combining pharmacy retail growth from Rite Aid assets with a stabilized health benefits arm, the company is diversifying its revenue streams to reduce reliance on any single sector of the healthcare market.